Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $88.89 Consensus Price Target from Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS) has received an average recommendation of “Buy” from the twelve research firms that are currently covering the stock, MarketBeat reports. Twelve research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $88.89.

A number of analysts have issued reports on the company. Guggenheim started coverage on Keros Therapeutics in a research report on Monday, September 23rd. They issued a “buy” rating and a $96.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $84.00 target price on shares of Keros Therapeutics in a research note on Thursday, November 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a report on Friday. Scotiabank started coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price target on the stock. Finally, Bank of America lowered their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th.

Keros Therapeutics Trading Up 1.2 %

NASDAQ KROS opened at $56.58 on Friday. The stock has a market cap of $2.29 billion, a PE ratio of -10.86 and a beta of 1.23. Keros Therapeutics has a twelve month low of $27.31 and a twelve month high of $73.00. The stock has a fifty day simple moving average of $59.32 and a 200-day simple moving average of $52.16.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Keros Therapeutics’s revenue was up 4750.0% on a year-over-year basis. During the same period in the previous year, the company posted ($1.33) EPS. Research analysts predict that Keros Therapeutics will post -5.28 EPS for the current year.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Keros Therapeutics by 14.5% during the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after acquiring an additional 324 shares in the last quarter. KBC Group NV increased its holdings in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after acquiring an additional 432 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. increased its holdings in shares of Keros Therapeutics by 36.7% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock valued at $223,000 after acquiring an additional 1,033 shares during the last quarter. Finally, Arizona State Retirement System raised its position in shares of Keros Therapeutics by 16.3% during the 2nd quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock worth $369,000 after acquiring an additional 1,130 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.